Articles
10 June 2009
Vol. 2 No. 14: Immunomodulatory drugs: the foundation for treating hematological malignancies Amsterdam, 15 June 2006
https://doi.org/10.4081/hmr.v2i14.509

Transfusion independence and cytogenetic response in myelodysplastic syndromes. What this means for the patient

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
194
Views
532
Downloads

Authors

Alan F. List
support@pagepress.org
Myelodysplastic syndromes (MDS) constitute a spectrum of hae matopoietic stem cell malignancies characterized by ineffective haematopoiesis, peripheral cytopenia, and increased risk of acute myeloid leukaemia (AML). Refractory anaemia is the presenting feature in approximately two-thirds of patients, with anaemia usually developing in the remainder as the disease progresses.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Transfusion independence and cytogenetic response in myelodysplastic syndromes. What this means for the patient. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.509